Premature Labor (Tocolysis) - Pipeline Review, H1 2018

  • ID: 4464910
  • Drug Pipelines
  • 52 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AMAG Pharmaceuticals Inc
  • GlaxoSmithKline Plc
  • Lipocine Inc
  • ObsEva SA
  • MORE
Premature Labor (Tocolysis) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Premature Labor (Tocolysis) - Pipeline Review, H1 2018, provides an overview of the Premature Labor (Tocolysis) (Women's Health) pipeline landscape.

Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Premature Labor (Tocolysis) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premature Labor (Tocolysis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Premature Labor (Tocolysis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis) (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Premature Labor (Tocolysis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Premature Labor (Tocolysis) (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Premature Labor (Tocolysis) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis) (Women's Health)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Premature Labor (Tocolysis) (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AMAG Pharmaceuticals Inc
  • GlaxoSmithKline Plc
  • Lipocine Inc
  • ObsEva SA
  • MORE
Introduction

The Publisher's Report Coverage

Premature Labor (Tocolysis) - Overview

Premature Labor (Tocolysis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Premature Labor (Tocolysis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development

AMAG Pharmaceuticals Inc

GlaxoSmithKline Plc

Juniper Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Lipocine Inc

ObsEva SA

Premature Labor (Tocolysis) - Drug Profiles

bedoradrine sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxyprogesterone caproate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxyprogesterone caproate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OBE-022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

progesterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

retosiban - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Acute Inflammation and Premature Labor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Premature Labor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Premature Labor (Tocolysis) - Dormant Projects

Premature Labor (Tocolysis) - Discontinued Products

Premature Labor (Tocolysis) - Product Development Milestones

Featured News & Press Releases

Dec 20, 2017: New Patent Issued to AMAG Pharmaceuticals Entitled “Methods of Reducing Risk of Preterm Birth”

Dec 05, 2017: ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor

Sep 11, 2017: ObsEva Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual Meeting

Jun 29, 2017: ObsEva Announces To Present on OBE022 at ESHRE 2017 Annual Meeting

Jun 26, 2017: AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector

Jun 26, 2017: Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth

May 18, 2017: ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE

Apr 17, 2017: AMAG Submits Supplemental New Drug Application to FDA for Makena (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use

Mar 17, 2017: ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor

Feb 02, 2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration

Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor

Jan 09, 2017: Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth

Oct 12, 2016: AMAG Pharmaceuticals Announces Achievement of Key Milestone in Next Generation Development Program for Makena

Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor

Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Premature Labor (Tocolysis), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Premature Labor (Tocolysis) - Pipeline by AMAG Pharmaceuticals Inc, H1 2018

Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H1 2018

Premature Labor (Tocolysis) - Pipeline by Juniper Pharmaceuticals Inc, H1 2018

Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018

Premature Labor (Tocolysis) - Pipeline by Lipocine Inc, H1 2018

Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H1 2018

Premature Labor (Tocolysis) - Dormant Projects, H1 2018

Premature Labor (Tocolysis) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Premature Labor (Tocolysis), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AMAG Pharmaceuticals Inc
  • GlaxoSmithKline Plc
  • Juniper Pharmaceuticals Inc
  • Kissei Pharmaceutical Co Ltd
  • Lipocine Inc
  • ObsEva SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll